{"id":"placebo-to-dupilumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking IL-4 and IL-13, dupilumab reduces inflammation and prevents the activation of various immune cells, including mast cells and eosinophils. This leads to a decrease in the production of IgE antibodies and a reduction in the symptoms associated with allergic diseases.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:43.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"},{"name":"Asthma with an eosinophilic phenotype"},{"name":"Chronic rhinosinusitis with nasal polyps"}]},"trialDetails":[{"nctId":"NCT07053423","phase":"PHASE4","title":"A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":218},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT05097287","phase":"PHASE4","title":"Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-12-16","conditions":"Asthma","enrollment":1324},{"nctId":"NCT06191315","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-01-03","conditions":"Wheezing, Asthma","enrollment":90},{"nctId":"NCT06881251","phase":"PHASE2","title":"A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-26","conditions":"Dermatitis, Atopic","enrollment":256},{"nctId":"NCT07330934","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-12-31","conditions":"Atopic Dermatitis","enrollment":403},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT05720325","phase":"PHASE2","title":"Dupilumab Effects Against Aeroallergen Challenge","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-03-29","conditions":"Asthma, Allergic","enrollment":88},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT03694158","phase":"PHASE4","title":"Investigating Dupilumab's Effect in Asthma by Genotype","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-09-08","conditions":"Asthma","enrollment":150},{"nctId":"NCT07399067","phase":"PHASE2","title":"A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-02-06","conditions":"Atopic Dermatitis","enrollment":120},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT06687967","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-28","conditions":"Lichen Simplex Chronicus","enrollment":142},{"nctId":"NCT06687980","phase":"PHASE3","title":"A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-25","conditions":"Lichen Simplex Chronicus","enrollment":138},{"nctId":"NCT05347771","phase":"PHASE2","title":"Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-04","conditions":"Asthma","enrollment":240},{"nctId":"NCT04148352","phase":"PHASE2","title":"Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy","status":"TERMINATED","sponsor":"Andrew J Long, PharmD","startDate":"2021-10-18","conditions":"Allergies Food Milk","enrollment":33},{"nctId":"NCT06101095","phase":"PHASE4","title":"A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-11-29","conditions":"Eosinophilic Oesophagitis","enrollment":69},{"nctId":"NCT05731128","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-01-12","conditions":"Colitis Ulcerative","enrollment":68},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT04743791","phase":"PHASE4","title":"Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Sally E. Wenzel MD","startDate":"2022-10-17","conditions":"Asthma","enrollment":30},{"nctId":"NCT03678545","phase":"PHASE2","title":"Dupilumab in Eosinophilic Gastritis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-05-15","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":41},{"nctId":"NCT04394351","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-01","conditions":"Eosinophilic Esophagitis (EoE)","enrollment":102},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT06824649","phase":"PHASE4","title":"Biologics in Chronic Rhinosinusitis With Nasal Polyposis","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03","conditions":"Chronic Sinusitis, Nasal Polyps","enrollment":504},{"nctId":"NCT04600362","phase":"PHASE2","title":"Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Technical University of Munich","startDate":"2021-03-30","conditions":"Nummular Eczema","enrollment":70},{"nctId":"NCT06226610","phase":"PHASE2","title":"Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic","status":"RECRUITING","sponsor":"Akron Children's Hospital","startDate":"2024-11-21","conditions":"Pruritis","enrollment":46},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT04033367","phase":"PHASE4","title":"SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-22","conditions":"Atopic Dermatitis","enrollment":188},{"nctId":"NCT04678882","phase":"PHASE3","title":"Dupilumab in Japanese Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-01-15","conditions":"Atopic Dermatitis","enrollment":62},{"nctId":"NCT04400318","phase":"PHASE4","title":"The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-06-20","conditions":"Asthma","enrollment":109},{"nctId":"NCT06193434","phase":"PHASE1","title":"A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-01-05","conditions":"Healthy Participants, Atopic Dermatitis Patients","enrollment":99},{"nctId":"NCT04975438","phase":"PHASE1","title":"Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-18","conditions":"Dermatitis, Atopic","enrollment":34},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04502966","phase":"PHASE2","title":"Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-09","conditions":"Allergic Rhinoconjunctivitis, Grass Pollen Allergy","enrollment":108},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT03679676","phase":"PHASE2","title":"Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-02-05","conditions":"Hypersensitivity, Food Allergy, Hypersensitivity, Food","enrollment":108},{"nctId":"NCT05545072","phase":"PHASE3","title":"Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-10-26","conditions":"Allergic Fungal Rhinosinusitis","enrollment":5},{"nctId":"NCT04442269","phase":"PHASE2","title":"Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-09-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":62},{"nctId":"NCT04380038","phase":"PHASE4","title":"Viral Infection in Asthma (VIA) Study","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-05-01","conditions":"Asthma","enrollment":60},{"nctId":"NCT04596189","phase":"PHASE4","title":"Dupilumab for Prevention of Recurrence of CRSwNP After ESS","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-05-25","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":30},{"nctId":"NCT04678856","phase":"PHASE3","title":"Dupilumab in CRSsNP","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-02","conditions":"Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis","enrollment":71},{"nctId":"NCT03861455","phase":"PHASE2","title":"Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2019-07-15","conditions":"Chronic Hand Eczema","enrollment":94},{"nctId":"NCT04200755","phase":"PHASE2","title":"Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2020-05-19","conditions":"Localized Scleroderma","enrollment":45},{"nctId":"NCT06461949","phase":"PHASE3","title":"Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray","status":"WITHDRAWN","sponsor":"National Institute on Deafness and Other Communication Disorders (NIDCD)","startDate":"2024-07-17","conditions":"Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma","enrollment":""},{"nctId":"NCT04203797","phase":"PHASE4","title":"A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-16","conditions":"Asthma","enrollment":40},{"nctId":"NCT03738397","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-02-21","conditions":"Atopic Dermatitis","enrollment":673},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT03682770","phase":"PHASE2","title":"Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-10-03","conditions":"Peanut Allergy","enrollment":148},{"nctId":"NCT05694884","phase":"PHASE2","title":"Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab","status":"UNKNOWN","sponsor":"ASLAN Pharmaceuticals","startDate":"2022-12-21","conditions":"Atopic Dermatitis","enrollment":75},{"nctId":"NCT04417894","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-14","conditions":"Moderate to Severe Atopic Hand and Foot Dermatitis","enrollment":133},{"nctId":"NCT03912259","phase":"PHASE3","title":"Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-12-19","conditions":"Atopic Dermatitis","enrollment":165},{"nctId":"NCT03749148","phase":"PHASE2","title":"Cholinergic Urticaria - Efficacy of Dupilumab","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-12-10","conditions":"Cholinergic Urticaria","enrollment":48},{"nctId":"NCT04244006","phase":"PHASE2, PHASE3","title":"A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2020-07-23","conditions":"Netherton Syndrome","enrollment":24},{"nctId":"NCT03633617","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-09-24","conditions":"Eosinophilic Esophagitis","enrollment":321},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT04791319","phase":"PHASE2","title":"A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Dermatitis, Atopic","enrollment":199},{"nctId":"NCT03884842","phase":"PHASE3","title":"Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-07-01","conditions":"Asthma","enrollment":24},{"nctId":"NCT03782532","phase":"PHASE3","title":"Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-01-25","conditions":"Asthma","enrollment":486},{"nctId":"NCT03359356","phase":"PHASE2","title":"Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-01-09","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT04512339","phase":"PHASE2","title":"Dupilumab in Severe Chronic Hand Eczema","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2020-08-01","conditions":"Hand Eczema","enrollment":30},{"nctId":"NCT03346434","phase":"PHASE2, PHASE3","title":"Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-30","conditions":"Dermatitis, Atopic","enrollment":202},{"nctId":"NCT04345367","phase":"PHASE3","title":"Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-11","conditions":"Atopic Dermatitis","enrollment":727},{"nctId":"NCT03387852","phase":"PHASE2","title":"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-12","conditions":"Asthma","enrollment":296},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT03749135","phase":"PHASE2","title":"Dupilumab in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-12","conditions":"Chronic Spontaneous Urticaria, Recurrent Angioedema","enrollment":72},{"nctId":"NCT03736967","phase":"PHASE2","title":"Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-11-12","conditions":"Atopic Dermatitis","enrollment":206},{"nctId":"NCT03389893","phase":"PHASE4","title":"Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-25","conditions":"Atopic Dermatitis (AD)","enrollment":72},{"nctId":"NCT03720470","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-29","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":838},{"nctId":"NCT03595488","phase":"PHASE2","title":"Dupilumab for Aspirin-exacerbated Respiratory Disease","status":"COMPLETED","sponsor":"Rochester General Hospital","startDate":"2018-09-05","conditions":"Aspirin-exacerbated Respiratory Disease","enrollment":11},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT02277769","phase":"PHASE3","title":"Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-11-30","conditions":"Dermatitis, Atopic","enrollment":708},{"nctId":"NCT03558997","phase":"PHASE2","title":"Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-06-07","conditions":"Allergic Rhinitis","enrollment":103},{"nctId":"NCT02210780","phase":"PHASE2","title":"Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-08-05","conditions":"Atopic Dermatitis","enrollment":194},{"nctId":"NCT01979016","phase":"PHASE2","title":"Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-12-31","conditions":"Atopic Dermatitis (AD)","enrollment":54},{"nctId":"NCT02395133","phase":"PHASE3","title":"A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-03-25","conditions":"Atopic Dermatitis","enrollment":422},{"nctId":"NCT01385657","phase":"PHASE1","title":"Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-07-31","conditions":"Atopic Dermatitis","enrollment":37},{"nctId":"NCT03112577","phase":"PHASE1","title":"Study of REGN3500 and Dupilumab in Patients With Asthma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-06-15","conditions":"Asthma, Allergic","enrollment":32},{"nctId":"NCT02898454","phase":"PHASE3","title":"Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-28","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":448},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT02912468","phase":"PHASE3","title":"A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-05","conditions":"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","enrollment":276},{"nctId":"NCT03054428","phase":"PHASE3","title":"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-03-21","conditions":"Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin","enrollment":251},{"nctId":"NCT02414854","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04-27","conditions":"Asthma","enrollment":1902},{"nctId":"NCT01548404","phase":"PHASE2","title":"Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-04","conditions":"Atopic Dermatitis","enrollment":109},{"nctId":"NCT02277743","phase":"PHASE3","title":"Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-10","conditions":"Dermatitis, Atopic","enrollment":671},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01639040","phase":"PHASE2","title":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":31},{"nctId":"NCT01859988","phase":"PHASE2","title":"Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-05","conditions":"Atopic Dermatitis","enrollment":380},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01920893","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-08","conditions":"Nasal Polyps","enrollment":60},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT01259323","phase":"PHASE1","title":"Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2010-12","conditions":"Dermatitis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":467,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to dupilumab","genericName":"Placebo to dupilumab","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process. Used for Moderate to severe atopic dermatitis, Asthma with an eosinophilic phenotype, Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}